The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combination regimens, such as Roche / Genentech’s Zelboraf + Cotellic, Novartis’s Tafinlar + Mekinist, and, more recently, Pfizer / Array BioPharma’s Braftovi + Mektovi, has significantly changed the treatment landscape for malignant melanoma in both the resectable and metastatic settings. Nonetheless, opportunities remain for novel agents specifically targeting the underpenetrated BRAF wild-type unresectable or metastatic population. With the expected introduction of novel agents and combination regimens, the malignant melanoma treatment algorithm will continue to evolve. In such a dynamic indication, marketed drugs need to be carefully positioned to achieve optimal uptake.

Questions Answered:

  • How large are the clinically and commercially relevant malignant melanoma drug-treatable populations? Will drug-treatment rates increase over the forecast period?
  • What is the current treatment landscape in malignant melanoma? Which currently approved drugs are the most important and why?
  • Which drugs in late-phase development are poised to change the treatment landscape for malignant melanoma and how? What sales/uptake could these drugs secure in the malignant melanoma market?
  • What are the key drivers and constraints in the malignant melanoma market, and how will the market evolve over the forecast period?

Content Highlights

Geographies: United States, EU5, Japan.

Primary research: 20 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed incidence of malignant melanoma by country, segmented by disease stage and BRAF mutation status.

Forecast: 10-year, annualized, drug-level sales and patient share of key malignant melanoma therapies through 2029, segmented by brands/generics and epidemiological subpopulations.

Emerging therapies: Phase III: 9 drugs; Phase II: 11 drugs; coverage of select preclinical and Phase I products.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Related Reports

Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast

The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/ME...

View Details

Malignant Melanoma - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key endometrial cancer pati...

View Details

Malignant Melanoma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of ma...

View Details

Malignant Melanoma - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into...

View Details